News & Blog

News & Blog

  • Reset
Blog | Dec 5 2024

Highlights of FA research from ICAR 2024

Research
News | Nov 19 2024

November 2024 – Advocacy Newsletter

Advocacy
News | Nov 18 2024

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Industry News
News | Nov 15 2024

Lexeo Therapeutics Announces Complete Enrollment of LX2006 SUNRISE-FA Phase 1/2 trial and Alignment with FDA on an Accelerated Approval Pathway

Industry News
News | Nov 14 2024

Larimar Therapeutics Announces Three Poster Presentations at the 2024 International Congress for Ataxia Research (ICAR) on November 12–15, 2024

Industry News
News | Nov 12 2024

Capsida Biotherapeutics to Present New Preclinical Data for Friedreich’s Ataxia Next-Generation Gene Therapy to Target CNS, Cardiac Tissues and Sensory Regions

Industry News
News | Nov 12 2024

Global Ataxia Advocacy Organizations Unite to Host Largest International Congress for Ataxia Research in London

FARA News | Research
Blog | Nov 11 2024

Meet The Community: Aidan LeCompte

Community
Blog | Nov 4 2024

2024 rideATAXIA Philly and FARA & CHOP FA Symposium Recap

Events
Blog | Oct 28 2024

Meet The Community: Daniel Huber

Community
Blog | Oct 21 2024

Meet The Community: Kendall Harvey

Community
News | Oct 16 2024

Papillon Therapeutics Receives Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia

Industry News